Squarepoint Ops LLC Acquires 5.1% Passive Stake in LENZ Therapeutics

On April 8, 2026, Squarepoint Ops LLC and its affiliated entities, including Squarepoint Capital LLP and Squarepoint Master Fund Limited, filed a Schedule 13G regarding their holdings in LENZ Therapeutics, Inc. (LENZ). The filing reveals that the reporting group has collectively acquired a 5.1% stake in the company, representing 1,593,246 shares of common stock. This transaction crossed the 5% disclosure threshold on April 1, 2026. Specifically, Squarepoint Master Fund Limited holds the majority of these shares (1,590,333), while Squarepoint Core Master Fund Limited holds a minor portion (2,913 shares). The filing was made under Rule 13d-1(c), indicating a passive investment intent with no current plans to influence or change the control of the issuer. The reporting persons share voting and dispositive power over the reported shares. This represents a significant new position for the Squarepoint group in the clinical-stage biotechnology company.